Global research and learning agenda for building evidence on contraceptive-induced menstrual changes for research, product development, policies, and programs [version 1; peer review: 2 approved]

Background: Contraceptive-induced menstrual changes (CIMCs) can affect family planning (FP) users’ lives in both positive and negative ways, resulting in both opportunities and consequences. Despite this, and despite the important links between FP and menstrual health (MH), neither field adequately...

Full description

Bibliographic Details
Main Authors: Kavita Nanda, Emily Hoppes, Julie Hennegan, Chukwuemeka Nwachukwu, Amanda Cordova-Gomez, Diana L. Blithe, Gustavo F. Doncel, Hilary Critchley, Lisa B. Haddad, Laneta J. Dorflinger, Jacqueline A. Maybin, Amelia C.L. Mackenzie, Carolina Sales Vieira, Kelle Moley, Alexandria Mickler, Simon P.S. Kibira, Chelsea B. Polis, Funmilola M. OlaOlorun, Katie M. Williams, Marni Sommer, Tanya Mahajan, Eva Lathrop, Kate H. Rademacher, Katrina Wilson, Marsden Solomon, Lillian Rountree, Lucy C. Wilson, Bellington Vwalika
Format: Article
Language:English
Published: F1000 Research Ltd 2022-04-01
Series:Gates Open Research
Subjects:
Online Access:https://gatesopenresearch.org/articles/6-49/v1
Description
Summary:Background: Contraceptive-induced menstrual changes (CIMCs) can affect family planning (FP) users’ lives in both positive and negative ways, resulting in both opportunities and consequences. Despite this, and despite the important links between FP and menstrual health (MH), neither field adequately addresses CIMCs, including in research, product development, policies, and programs globally. Methods: In November 2020, a convening of both MH and FP experts reviewed the existing evidence on CIMCs and identified significant gaps in key areas. Results: These gaps led to the establishment of a CIMC Task Force in April 2021 and the development of the Global Research and Learning Agenda: Building Evidence on Contraceptive-Induced Menstrual Changes in Research, Product Development, Policies, and Programs Globally (the CIMC RLA), which includes four research agendas for (1) measurement, (2) contraceptive research and development (R&D) and biomedical research, (3) social-behavioral and user preferences research, and (4) programmatic research. Conclusions: Guided by the CIMC RLA, researchers, product developers, health care providers, program implementers, advocates, policymakers, and funders are urged to conduct research and implement strategies to address the beneficial and negative effects of CIMCs and support the integration of FP and MH. CIMCs need to be addressed to improve the health and well-being of women, girls, and other people who menstruate and use contraceptives globally. Disclaimer: The views expressed in this article are those of the authors. Publication in Gates Open Research does not imply endorsement by the Gates Foundation.
ISSN:2572-4754